RGDXQ (Response Genetics) Growth Rank : 0 (As of Sep. 22, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Response Genetics Growth Rank?

Response Genetics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Response Genetics Growth Rank Related Terms

Thank you for viewing the detailed overview of Response Genetics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Response Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070

Website

http://www.responsegenetics.com

Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.

Executives

Roberto Mignone	10 percent owner	C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber	director	15 TROTTERS LANE, MONROE CT 06468
Sam Chawla	director	1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris	officer: Vice President and CFO	345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya	director	C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna	director, officer: Chief Executive Officer	4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor • 12-14-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-14-2010

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-22-2009